Results 131 to 140 of about 41,447 (182)
Some of the next articles are maybe not open access.
Biotherapy of chronic myelogenous leukemia
Annals of Hematology, 1995The aim of this review is to summarize the current knowledge on the clinical results of biotherapy of chronic myelogenous leukemia (CML) and potential mechanisms of the antitumor action of interferon alpha. IFN alpha treatment induces hematologic and cytogenetic remissions in patients with chronic phase CML.
W E, Aulitzky +3 more
openaire +2 more sources
Hypercalcemia in Chronic Myelogenous Leukemia
New England Journal of Medicine, 1970SERUM calcium concentration may be elevated in any neoplastic disorder associated with bone destruction, either primary or metastatic. However, relatively few cases of hypercalcemia and bone destruction have been observed in conjunction with leukemia.1 2 3 4 5 6 7 8 9 In the majority of previously reported cases of hypercalcemia, the patients have had ...
H S, Ballard, A J, Marcus
openaire +2 more sources
Chronic myelogenous leukemia in the dog
Journal of the American Veterinary Medical Association, 1983SUMMARY Chronic myelogenous leukemia was diagnosed in 7 dogs. In each case, marked neutrophilia in the absence of infection was observed in association with nonspecific illness. Diagnosis was based on morphologic cytology of blood smears, bone marrow aspirates, and in 1 case, a lymph node biopsy specimen.
C E, Leifer +3 more
openaire +2 more sources
Immunotherapy in Chronic Myelogenous Leukemia
Clinical Lymphoma and Myeloma, 2007Chronic myelogenous leukemia is one of the leukemic disorders more responsive to immunotherapy. Interferon-based regimens were the first treatment to produce complete cytogenetic responses, and this agent has been classified as an immunotherapeutic agent.
François, Guilhot +4 more
openaire +2 more sources
Autografting for chronic myelogenous leukemia
Current Opinion in Hematology, 1995Two thirds of patients with chronic myelogenous leukemia do not have suitable donors for allogeneic transplantation. As for other leukemias, autografting may potentially be curative, because normal Ph- hematopoietic stem cells persist in the marrow and blood of patients with chronic myelogenous leukemia.
R, Bhatia, C M, Verfaillie
openaire +2 more sources
Chronic myelogenous leukemia: A review
The American Journal of Medicine, 1996Chronic myelogenous leukemia (CML) is a chronic myeloproliferative disorder with an initially chronic course lasting for 3-5 years. It eventually transforms into accelerated and blastic phases, which are generally fatal. CML was one of the first diseases in which a specific chromosomal abnormality was identified, a t(9;22)(q34;q11) or Philadelphia ...
J E, Cortes, M, Talpaz, H, Kantarjian
openaire +2 more sources
Current Opinion in Oncology, 2003
Within the past few years, the introduction of imatinib mesylate (imatinib) has profoundly changed the management of patients with chronic myelogenous leukemia. This review article addresses the recent advances in the treatment of chronic myelogenous leukemia--in particular, maturing data on the use of imatinib in different phases of the disease; the ...
openaire +2 more sources
Within the past few years, the introduction of imatinib mesylate (imatinib) has profoundly changed the management of patients with chronic myelogenous leukemia. This review article addresses the recent advances in the treatment of chronic myelogenous leukemia--in particular, maturing data on the use of imatinib in different phases of the disease; the ...
openaire +2 more sources
Clinical Journal of Oncology Nursing, 2005
Chronic myelogenous leukemia (CML) represents about 14% of all leukemias and occurs with a frequency of about 1 in 100,000. It is rare in children. Symptoms include fatigue, weight loss, sweating, and abdominal discomfort from an enlarged spleen. The white blood cell count can range from 100-600 ul.
openaire +2 more sources
Chronic myelogenous leukemia (CML) represents about 14% of all leukemias and occurs with a frequency of about 1 in 100,000. It is rare in children. Symptoms include fatigue, weight loss, sweating, and abdominal discomfort from an enlarged spleen. The white blood cell count can range from 100-600 ul.
openaire +2 more sources
Cancer, 1978
Chronic myelogenous leukemia (CML) is a relatively rare disease, with a number of features that make it especially suitable for observations on leukemogenesis in man. These include known etiologic agents, often a prolonged preclinical and active stage, cells with identifiable morphological and histochemical characteristics and the presence of the ...
openaire +2 more sources
Chronic myelogenous leukemia (CML) is a relatively rare disease, with a number of features that make it especially suitable for observations on leukemogenesis in man. These include known etiologic agents, often a prolonged preclinical and active stage, cells with identifiable morphological and histochemical characteristics and the presence of the ...
openaire +2 more sources
BIOLOGY OF CHRONIC MYELOGENOUS LEUKEMIA
Hematology/Oncology Clinics of North America, 1998This article reviews the biology of chronic myelogenous leukemia (CML) and its effect on the process of hematopoiesis. The relevance of the BCR-ABL fusion protein as well as murine models are also discussed. CML has been studied more extensively than any other malignancy, yet the correlation between the clinical symptoms of chronic phase CML and the ...
openaire +2 more sources